DexCom Inc. (DXCM)

99.56
NASDAQ : Health Technology
Prev Close 99.74
Day Low/High 99.46 / 101.87
52 Wk Low/High 42.62 / 102.10
Avg Volume 1.10M
Exchange NASDAQ
Shares Outstanding 88.08M
Market Cap 8.79B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Jim Cramer says there's the market that's about entertainment and anything that delivers entertainment to you. And then there's everything else.

Dexcom G6® CGM System Receives CE Mark

Dexcom G6® CGM System Receives CE Mark

Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up.

Dexcom G5 Continuous Glucose Monitoring System Now Available On Mobile, Smart Devices For Medicare Patients With Diabetes

Dexcom G5 Continuous Glucose Monitoring System Now Available On Mobile, Smart Devices For Medicare Patients With Diabetes

Dexcom, Inc. ( NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and Corporate Development, and Matthew Dolan, Vice President...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRL, DXCM, EVTC, GEC, KRC, WRLD, WWW Downgrades: ACIW, DHT, MDP, PPC, SPKE, SUN, SYMC Initiations: AYX, CLPR, EGC Read on to get TheStreet Quant Ratings' detailed report:

DexCom Reports First Quarter 2018 Financial Results

DexCom Reports First Quarter 2018 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended March 31, 2018.

DexCom Schedules First Quarter 2018 Earnings Release And Conference Call For May 2, 2018 At 4:30 P.m. Eastern Time.

DexCom Schedules First Quarter 2018 Earnings Release And Conference Call For May 2, 2018 At 4:30 P.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2018 financial results after market close on Wednesday, May 2, 2018.

PayPal, Advanced Micro Devices, Intel: 'Mad Money' Lightning Round

PayPal, Advanced Micro Devices, Intel: 'Mad Money' Lightning Round

Jim Cramer highlights PayPal, Advanced Micro Devices, Intel, Nvidia, DexCom and CVS Health.

FANG Stocks Strike Back: Cramer's 'Mad Money' Recap (Thursday 3/29/18)

FANG Stocks Strike Back: Cramer's 'Mad Money' Recap (Thursday 3/29/18)

Jim Cramer says if you can't handle the newsflow, both real and fake, you may need to use this rally to lighten up. But if you can, then hold on, stick around and make money.

FDA Authorizes Marketing Of The New Dexcom G6® CGM Eliminating Need For Fingerstick Blood Testing For People With Diabetes

FDA Authorizes Marketing Of The New Dexcom G6® CGM Eliminating Need For Fingerstick Blood Testing For People With Diabetes

DexCom, Inc. ( NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) is pleased to announce that the U.

WaveForm Technologies Receives Favorable Decision On Critical Glucose Monitoring Patents

WaveForm Technologies Receives Favorable Decision On Critical Glucose Monitoring Patents

The US Patent Office Patent Trial and Appeal Board recently ruled to uphold the validity of WaveForm Technologies Inc. patents in the emerging field of continuous glucose monitoring

DexCom Reports Record Fourth Quarter And Fiscal Year 2017 Financial Results

DexCom Reports Record Fourth Quarter And Fiscal Year 2017 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2017.

Jim's Daily Rundown

Jim discusses Comcast's bid for Sky, Broadcom, Fed Chair Powell's testimony and more.

Fitbit Shares Crater 16% After Brutal Guidance

Fitbit Shares Crater 16% After Brutal Guidance

Fitbit shares dropped 13% in after-hours trading on Monday after the company missed on earnings and revenue for its fiscal fourth quarter.

Fitbit Shares Tumble After Missing Earnings Estimates

Fitbit Shares Tumble After Missing Earnings Estimates

Fitbit shares fell about 12% after hours on Monday after missing on both the top and bottom lines.

DexCom Announces Upcoming Conference Presentations

DexCom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conferences: Steven Pacelli, Executive Vice President, Strategy and Corporate...

DexCom Schedules Fourth Quarter And Full Year 2017 Earnings Release And Conference Call For February 27, 2018 At 4:30 P.m. Eastern Time.

DexCom Schedules Fourth Quarter And Full Year 2017 Earnings Release And Conference Call For February 27, 2018 At 4:30 P.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2017 financial results after market close on Tuesday, February 27, 2018.

UnitedHealthcare And Dexcom Bring Wearable Technology Solution, One-on-One Coaching To People Battling Type 2 Diabetes

UnitedHealthcare And Dexcom Bring Wearable Technology Solution, One-on-One Coaching To People Battling Type 2 Diabetes

UnitedHealthcare, the market leader in Medicare benefit plans 1, and DexCom, Inc.

DexCom Reports Record Preliminary, Unaudited Revenue For The Fourth Quarter And Fiscal Year 2017 And Provides Initial 2018 Outlook

DexCom Reports Record Preliminary, Unaudited Revenue For The Fourth Quarter And Fiscal Year 2017 And Provides Initial 2018 Outlook

DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring ("CGM"), today reported that it achieved preliminary, unaudited revenue of approximately $218 million for the fourth quarter ended December 31, 2017,...

Weekly Roundup

Callout: Fed raises interest rates, stocks grind higher

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Kevin Sayer, President and Chief Executive Officer, will present an...

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

TheStreet recounts the successes and failures of the biggest names in the activism game.

Weekly Roundup

Stocks finish higher in an up and down week.

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Quentin Blackford, Executive Vice President, Chief Financial Officer;...

Weekly Roundup

Oil hits highest level since 2015 in holiday-shortened week. We drop a name from the portfolio.

Dexcom, Lilly Team Up on Diabetes System

Companies aim to improve disease management.

Dexcom Announces Development Agreement With Lilly To Integrate Dexcom CGM Into Connected Diabetes Ecosystem

Dexcom Announces Development Agreement With Lilly To Integrate Dexcom CGM Into Connected Diabetes Ecosystem

DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a development agreement with Eli Lilly and Company (NYSE: LLY) to include Dexcom CGM into Lilly's...

TheStreet Quant Rating: C- (Hold)